HDAC1 and in situ carcinoma: Strong staining of HDAC-1 and HDAC-2 was associated with higher grading (both WHO 1973 and 2004), additionally tumours with high expression levels of HDAC-2 presented more often with adjacent carcinoma in situ compared to tumours with weak HDAC-2 staining.